Seal Biosciences Seal Biosciences Seal Biosciences Seal Biosciences Seal Biosciences

Oncotarget vol.6

  • June 30, 2015
150 150 Seal Biosciences


Unexpected insights for anti-EGFR cancer therapy

Philippe Depeille, Robert S. Warren and Jeroen P. Roose

Colorectal cancer (CRC) is a major cause of morbidity and mortality. It accounts for over 9% of all malignancies, making it the third most common cancer worldwide and second most common cause of death in the developed world. Treatment of metastatic colorectal cancer (mCRC) is largely palliative, making potentially curative therapy via molecular inhibition of specific cellular targets in CRC a highly sought-after goal.

READ MORE

http://www.sealbiosciences.com/wp-content/uploads/2018/03/Depeile-OncoTarget-2015.pdf